Warning: Wrong parameter count for strstr() in /users/0028/jumar/www/public_html/food/sqlfunc.php on line 109
Krzyżanowska P., Walkowiak J., 2010. Vitamin K status in cystic fibrosis patients. Acta Sci.Pol. Technol. Aliment. 9 (4), 463-467

Wydawnictwo Uniwersytetu Przyrodniczego w Poznaniu

Biblioteka Uniwersytetu Przyrodniczego w Poznaniu

Nauka Przyroda Technologie

Thomson Routers Master List

Scopus

Ebsco

Directory of Open Acces Journals

CBR- Open Access Journals in Poland

FOOD SCIENCE CENTRAL

Index Copernicus Journal Master List

Pubmed Medline

Polska Bibliografia Naukowa

Creaive Commons

Creative Commons licence CC BY-NC (Attribution-NonCommercial)
Issue 9 (4) 2010 pp. 463-467

Patrycja Krzyżanowska, Jarosław Walkowiak

Poznań University of Medical Sciences

Vitamin K status in cystic fibrosis patients

Abstract

Vitamin K belongs to the family of fat-soluble vitamins and plays an important role in hemostasis, bone metabolism and may affect cerebral sphingolipid synthesis. It is a cofactor necessary for posttranslational γ-carboxylation of glutamyl residues in selected proteins such as the osteocalcin, and procoagulation factors II, VII, IX, X. Vitamin K deficient individuals appear to have more undercarboxylated proteins, which are functionally defective. The vitamin K deficiency has been frequently documented in patients with cystic fibrosis. The main possible causes of this deficiency include: fat malabsorption due to pancreatic exocrine insufficiency, cholestatic or  noncholestatic liver disease, reduced production of vitamin K by colonic flora related to chronic antibiotic treatments, bowel resections and increased mucous accumulation in the bowel. CF patients are more prone to osteopenia, caused by chronic vitamin K shortage, than to coagulopathy. Despite available evidence, which strongly suggests that all CF patients are at risk for developing vitamin K deficiency, its supplementation doses have not been established. Recent recommendations from Europe and the UK have suggested varied doses ranging from 0.3 mg/day to 10 mg/week. Further studies, both cross sectional and longitudinal interventional, are still required to determine routine and therapeutic supplementation doses.

Keywords: cystic fibrosis, vitamin K, osteocalcin, undercarboxylated prothrombin, PIVKA-II
pub/.pdf Full text available in english in Adobe Acrobat format:
http://www.food.actapol.net/issue4/volume/6_4_2010.pdf

For citation:

MLA Krzyżanowska, Patrycja, and Jarosław Walkowiak. "Vitamin K status in cystic fibrosis patients." Acta Sci.Pol. Technol. Aliment. 9.4 (2010): 463-467.
APA Krzyżanowska P., Walkowiak J. (2010). Vitamin K status in cystic fibrosis patients. Acta Sci.Pol. Technol. Aliment. 9 (4), 463-467
ISO 690 KRZYżANOWSKA, Patrycja, WALKOWIAK, Jarosław. Vitamin K status in cystic fibrosis patients. Acta Sci.Pol. Technol. Aliment., 2010, 9.4: 463-467.